AN2 Therapeutics to Participate at Upcoming Investor Conferences
AN2 Therapeutics (Nasdaq: ANTX), a biopharmaceutical company specializing in boron chemistry-based small molecule therapeutics, has announced its participation in two major investor conferences this December. The company will present at the 7th Annual Evercore HealthCONx Conference (December 3-5, 2024), where CEO Eric Easom will deliver a corporate overview on December 4. Additionally, management will attend Oppenheimer's Movers in Rare Disease Summit on December 12, 2024, for one-on-one meetings.
The Evercore presentation will be available via webcast on AN2 Therapeutics' website, with a replay accessible for 30 days afterward.
AN2 Therapeutics (Nasdaq: ANTX), un'azienda biopharmaceutica specializzata in terapie a base di piccole molecole di chimica del boro, ha annunciato la sua partecipazione a due importanti conferenze per investitori questo dicembre. L'azienda presenterà al 7° Annual Evercore HealthCONx Conference (3-5 dicembre 2024), dove il CEO Eric Easom fornirà una panoramica aziendale il 4 dicembre. Inoltre, la direzione parteciperà al Summit Oppenheimer's Movers in Rare Disease il 12 dicembre 2024, per incontri one-to-one.
La presentazione di Evercore sarà disponibile tramite webcast sul sito di AN2 Therapeutics, con una riproposizione accessibile per 30 giorni successivamente.
AN2 Therapeutics (Nasdaq: ANTX), una compañía biofarmacéutica especializada en terapias de pequeñas moléculas basadas en química de boro, ha anunciado su participación en dos importantes conferencias de inversores este diciembre. La compañía presentará en la 7ª Conferencia Anual Evercore HealthCONx (3-5 de diciembre de 2024), donde el CEO Eric Easom entregará una visión general de la empresa el 4 de diciembre. Además, la dirección asistirá al Summit Movers in Rare Disease de Oppenheimer el 12 de diciembre de 2024, para reuniones uno a uno.
La presentación de Evercore estará disponible a través de webcast en el sitio web de AN2 Therapeutics, con una repetición accesible durante 30 días después.
AN2 Therapeutics (Nasdaq: ANTX)는 붕소 화학 기반의 소분자 치료제를 전문으로 하는 생명공학 회사로, 이번 12월에 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 제7회 Evercore HealthCONx Conference (2024년 12월 3-5일)에 발표할 예정이며, CEO인 Eric Easom이 12월 4일에 기업 개요를 발표합니다. 또한 경영진은 2024년 12월 12일 Oppenheimer의 희귀질환 서밋에 참석하여 일대일 회의를 진행할 예정입니다.
Evercore 발표는 AN2 Therapeutics 웹사이트를 통해 웹캐스트로 제공되며, 이후 30일 동안 다시 시청할 수 있습니다.
AN2 Therapeutics (Nasdaq: ANTX), une entreprise biopharmaceutique spécialisée dans les thérapies de petites molécules basées sur la chimie du bore, a annoncé sa participation à deux grandes conférences pour investisseurs ce décembre. L'entreprise présentera lors de la 7ème Conférence Annuelle Evercore HealthCONx (du 3 au 5 décembre 2024), où le PDG Eric Easom donnera un aperçu de l'entreprise le 4 décembre. De plus, la direction assistera au Sommet Oppenheimer's Movers in Rare Disease le 12 décembre 2024, pour des réunions en tête-à-tête.
La présentation d'Evercore sera disponible via un webinaire sur le site web d'AN2 Therapeutics, avec une rediffusion accessible pendant 30 jours par la suite.
AN2 Therapeutics (Nasdaq: ANTX), ein biopharmazeutisches Unternehmen, das auf kleine Molekültherapien auf Basis der Bor-Chemie spezialisiert ist, hat seine Teilnahme an zwei großen Investorenkonferenzen im Dezember angekündigt. Das Unternehmen wird auf der 7. jährlichen Evercore HealthCONx-Konferenz (3.-5. Dezember 2024) präsentieren, wo CEO Eric Easom am 4. Dezember eine Unternehmensübersicht geben wird. Darüber hinaus wird das Management am Oppenheimer's Movers in Rare Disease Summit am 12. Dezember 2024 an individuellen Treffen teilnehmen.
Die Präsentation von Evercore wird über ein Webcast auf der Website von AN2 Therapeutics verfügbar sein, mit einer Wiederholung, die 30 Tage lang zugänglich ist.
- None.
- None.
Details of the events are as follows:
7th Annual Evercore HealthCONx Conference, December 3-5, 2024
- Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Wednesday, December 4 at 8:20am ET
Oppenheimer’s Movers in Rare Disease Summit, December 12, 2024
- Members of management will be available for 1X1 meetings on Thursday, December 12, 2024
A webcast of the Evercore HealthCONx Conference presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241114578103/en/
COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com
Source: AN2 Therapeutics, Inc.
FAQ
When is AN2 Therapeutics (ANTX) presenting at the Evercore HealthCONx Conference 2024?
Which investor conferences is AN2 Therapeutics (ANTX) attending in December 2024?
How long will the AN2 Therapeutics (ANTX) Evercore Conference webcast be available?
What type of meetings will AN2 Therapeutics (ANTX) hold at the Oppenheimer Summit?
